All News
RheumNow Podcast – Infection in ANCA-Associated Vasculitis (3.26.2021)
Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.
Read Article
FDA Panel Rejects Tanezumab for Osteoarthritis
A two day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab, a nerve growth factor inhibitor, for use in osteoarthritis (OA).
Read Article
RheumNow Podcast – Infection in ANCA-Associated Vasculitis
Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on https://t.co/4GKxMY5Lll
https://t.co/joi1puBSuX
Dr. John Cush RheumNow ( View Tweet)
#RNL2021 coverage from @KDAO2011 #RheumNow https://t.co/GBnlyvPaz1
Dr. John Cush RheumNow ( View Tweet)
Are You a Super Rheum?
https://t.co/omvQXwhcoV https://t.co/8iQaRAi5di
Links:
Dr. John Cush RheumNow ( View Tweet)
Analysis of CPRD registry and 15670 MTX treated pts (46,571 PYs) showed discontinuation for abnormal or severely abnormal labs was 42/1000PY and 6/1,000PY; half that after Yr 1 (22 & 2.84). D/C for severe labs was 1 in 169 Yr1 & 1 in 352 per year after https://t.co/Dx91YqjplT
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2021 Highlights: Future Therapeutics for Rheumatoid Arthritis and Lessons Learned
https://t.co/NxLyHeI2f4 https://t.co/df7lPEia0D
Links:
Dr. John Cush RheumNow ( View Tweet)
News Feature: FDA Panel Rejects Tanezumab for Osteoarthritis
A 2 day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab for use in OA.
https://t.co/ltKmm9Nl1y https://t.co/qTWhSX9LBd
Links:
Dr. John Cush RheumNow ( View Tweet)
The Reflecting Rheum: Top Publications from 2020 Covering SpA and Still’s Disease
Sponsored by Novartis Medical Affairs
Listen to a panel of experts share their views on top spondyloarthritis and Still’s disease publications from 2020.
View Now: https://t.co/Kp2drDAqFv https://t.co/tjkUpxcMdT
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2021 coverage from @uptoTate #RheumNow https://t.co/u11ltNc2vA
Dr. John Cush RheumNow ( View Tweet)
The RheumNow podcast is up--Great Associations
Dr. Jack Cush rants on the journal reports, news and FDA actions featured last week on RheumNow.
https://t.co/gzWVbL8xMJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Claims data analysis (MarketScan, Medicare, Optum) of 87,653 RA patients starting either TNF inhibitor or tofacitinib shows venous thromboembolism (VTE) is rare (<1 per 100) RA Rx with either. VTE risk was same for Tofa and TNFi (HR of 1.13 [0.77-1.65]) https://t.co/UoMQRp12vo
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2021 https://t.co/bZdTYFdEn4
Dr. John Cush RheumNow ( View Tweet)
News Feature: Safety of Paternal DMARD or Biologic Use
https://t.co/9jCNJ9rHYF https://t.co/SIRPcPQxyB
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 162 ANCA-Assoc Vasculitis patients (63% GPA, 37% MPA) - risk of serious infx was 7.5 per 100Pt-Yrs & was higher with cyclophosphamide that RTX induction. Risks for SIE:plasmapheresis dialysis & high BVAS in 1st year https://t.co/kAlz9aGQup
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Fleischmann vs. Dr. Matsumoto: get rid of MTX vs. get rid of biologic in RA remission. Both argue on sustained remission, risk for anti-drug antibodies, longterm safety. Dr. Buch’s perfect answer… “it depends on patient’s preference, cost.” #RNL2021 https://t.co/FBf2uoDx0B
k dao KDAO2011 ( View Tweet)
Why Pain Consults present Not Taking Pain Meds
https://t.co/75YO027Oh6 https://t.co/rir90gM7qv
Links:
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Gr Rounds - Dr Saag
Rules around genetic testing for HLA-B5801 @UTSWIMchief @KenSaag https://t.co/QCpKv0J2s2
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Gran Rounds - Dr. Ken Saag, Anakinra vs IA steroids @UTSWIMchief @KenSaag https://t.co/M2UCbyuJpb
Dr. John Cush RheumNow ( View Tweet)
Dr. Ken Saag giving Rheum Grand Rounds at UT Southwestern. Data showing lower dose colchicine is safer than higher dose in acute gout @UTSWIMchief @KenSaag https://t.co/5KAn9SWlrU
Dr. John Cush RheumNow ( View Tweet)